Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Mining firms lift FTSE 100 to record high after Trump confirms 50% copper tariff
Join CNBC for live updates on European markets.
Wedbush, Dan Ives launch new ETF to capture the AI boom
The fund will track an evolving index of artificial intelligence plays, based on Ives’ research.
Trump Media shares fall nearly 10% after DJT plunge triggers trading halt
Trading in Trump Media shares was briefly halted due to volatility, after the Truth Social owner’s stock suddenly plunged in price.